A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

被引：1

作者：

Kastritis, Efstathios ^{[1
]}

Matous, Jeffrey, V ^{[2
]}

Abro, Emad Uddin ^{[3
]}

Eves, P. Taylor ^{[4
]}

Zheng, Cheng ^{[5
]}

Fiorino, Tony ^{[4
]}

Berdeja, Jesus ^{[6
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia

[4] Zentalis Pharmaceut, New York, NY USA

[5] Zentalis Pharmaceut Inc, New York, NY USA

[6] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158617

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4438 / 4439

页数：2

共 22 条

[1] A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
Nowakowski, Grzegorz S.
Leslie, Lori A.
Joffe, Erel
Rosenthal, Allison C.
Lunning, Matthew A.
Patel, Krish
Mead, Monica
Landsburg, Daniel J.
Fenske, Timothy S.
Ramchandren, Radhakrishnan
Geethakumari, Praveen Ramakrishnan
Skarbnik, Alan
Martinez, Elizabeth
Lieberman, Christopher
von Roemeling, Reinhard
Tun, Han W.
BLOOD, 2020, 136
[2] A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma
Younes, Anas
Batlevi, Connie Lee
Cohen, Jonathon B.
de Vos, Sven
Landsburg, Daniel J.
Myint, Zaw Win
Patel, Krish
Phillips, Tycel J.
Smith, Sonali M.
Westin, Jason R.
Ma, Anna W.
Grayson, Dena
von Roemeling, Reinhard
Barta, Stefan K.
BLOOD, 2019, 134
[3] A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
Smith, Catherine Choy
Vachhani, Pankit
Garcia-Manero, Guillermo
Grieselhuber, Nicole Renee
Murthy, Guru Subramanian Guru
Bhatia, Astha
Arora, Jatinder
Izadi, Hooman
Fiorino, Anthony
Rampal, Raajit
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)
Sun, Mingyuan
Qi, Junyuan
Chen, Zi
Zhang, Hongli
Song, Yongping
Shen, Aizong
Liu, Huilan
Huang, Jianying
Zhou, Fuling
Jin, Jie
Lu, Ming
Ahmad, Mohammad
Men, Lichuang
Cen, Wan
Yang, Dajun
Wang, Jianxiang
Zhai, Yifan
BLOOD, 2021, 138 : 3730 - +
[5] A phase I dose-escalation study of ZN-d5, an BCL-2 inhibitor with improved selectivity, in patients with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML)
Zaucha, J. M.
Fiorino, T.
Kalro, A.
Shin, H-J.
Viiala, N.
Torres, L.
Gordon, G.
Kirshoff, R.
Lopez, S.
Makris, L.
Miller, C.
Park, S.
Voliotis, D.
ANNALS OF ONCOLOGY, 2021, 32 : S617 - S617
[6] A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM).
Richardson, PG
Jagannath, S
Schlossman, R
Zeldenrust, S
Rajkumar, S
Alsina, M
Desikan, KR
Mitsiades, CS
Kelly, K
Doss, D
McKenney, M
Gorelik, S
Warren, D
Freeman, A
Rich, R
Knight, R
Olesnyckyj, M
Patin, J
Zeldis, J
Dalton, W
Anderson, KC
BLOOD, 2003, 102 (11) : 235A - 235A
[7] Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study
Karol, Seth E.
Cooper, Todd M.
Bittencourt, Henrique
Gore, Lia
O'Brien, Maureen M.
Fraser, Christopher
Gambart, Marion
Cario, Gunnar
Zwaan, Christian Michel
Bourquin, Jean-Pierre
Loh, Mignon L.
Caron, Hubert
Prine, Betty
Salem, Ahmed Hamed
Unnebrink, Kristina
Tong, Bo
Palenski, Tammy
Place, Andrew E.
BLOOD, 2019, 134
[8] Phase 1/2 open-label, multi-center study to assess the safety, tolerability and efficacy of a single dose of PBGM01 delivered into the cisterna magna of subjects with type 1 (early onset) and type 2a (late onset) infantile GM1 gangliosidosis
Jarnes, Jeanine R.
Day-Salvatore, Debra L.
Ficicioglu, Can
Hastings, Caroline
Bernard, Genevieve
Baruteau, Julien
Ezgu, Fatih
Giugliani, Roberto
Inbar-Feigenberg, Michal
Whitley, Chester B.
Ni, Yan
Ballard, Victoria L.
Haws, Thomas F.
Weinstein, David A.
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S62 - S63
[9] Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
Laubach, Jacob P.
Raje, Noopur
Yee, Andrew J.
Armand, Philippe
Schlossman, Robert L.
Rosenblatt, Jacalyn
Martin, Michael G.
Reynolds, Craig
Shain, Kenneth H.
Zackon, Ira
Stampleman, Laura V.
Lai, Emily
Caola, Aaron M.
Cappuccio, Joseph M.
Rivotto, Bradley
Reyes, Kaitlen
Savell, Alexandra
Henrick, Patrick
Pearce, Tillman
Handisides, Damian
Kroll, Stew
Anderson, Kenneth C.
Richardson, Paul G.
Ghobrial, Irene M.
BLOOD, 2016, 128 (22)
[10] A phase II, multi-center study of the EZH2 inhibitor, tazemetostat, in adult subjects with INI1-negative tumors including renal medullary carcinoma (RMC), or relapsed/refractory synovial sarcoma
Tannir, Nizar M.
Pressey, Joseph
Roche, Maria
Rodstrom, Jill
Blakemore, Stephen
Clawson, Alicia
Daigle, Scott
Gounder, Mrinal
BJU INTERNATIONAL, 2016, 118 : 14 - 14

← 1 2 3 →